Can Anti-Diarrhea meds make a powerful breast cancer drug safer?
NCT ID NCT05520723
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether adding loperamide (Imodium) and a white blood cell booster (G-CSF) could reduce severe diarrhea and low white blood cell counts caused by the drug Trodelvy in people with advanced breast cancer. Fifty patients with metastatic triple-negative or luminal breast cancer who had already tried other treatments took part. The goal was to see if these supportive medicines could make Trodelvy easier to tolerate without reducing its effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab govitecan (Trodelvy) plus loperamide and G-CSF
What this could lead to
If successful, this approach could make Trodelvy safer and more tolerable for patients with advanced breast cancer, reducing severe side effects like diarrhea and infections.
What could go wrong
This is a small, early-phase trial with only 50 participants and no comparison group. The supportive medications may not significantly reduce side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Arnau de Vilanova
Lleida, Lleida, Spain
-
Hospital Quiron San Camilo- Ruber Juan Bravo
Madrid, Madrid, 28006, Spain
-
Hospital Quirón Valencia
Valencia, Valencia, Spain
-
Hospital Ramón y Cajal
Madrid, Spain
-
Hospital Universitario A Coruña
A Coruña, A Coruna, Spain
-
Hospital Universitario Clínico San Cecilio de Granada
Granada, Spain
-
Hospital Universitario Donostia
San Sebastián, Donostia, 20014, Spain
-
Hospital Universitario General de Catalunya
Sant Cugat del Vallès, Barcelona, 08190, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Spain
-
Hospital de Sant Joan Despí - Moises Broggi
Barcelona, Spain